Evaluation of the Canadian Rheumatology Association Choosing Wisely recommendation concerning anti-nuclear antibody (ANA) testing

Clinical Rheumatology

Volumn 34, Issue 9, 2015, Pages 1551-1556

  Ferrari, Robert ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Anti cyclic citrullinated antibody; Anti nuclear antibody; Pain; Rheumatoid arthritis; Rheumatoid factor; Systemic lupus erythematosus

Indexed keywords

ANTINUCLEAR ANTIBODY; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; RHEUMATOID FACTOR; CYCLOPEPTIDE;

ADULT; ANTI NUCLEAR ANTIBODY TESTING; ARTICLE; CONNECTIVE TISSUE DISEASE; DISEASE DURATION; FEMALE; FOLLOW UP; HUMAN; IMMUNOLOGICAL PROCEDURES; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; AGED; ALBERTA; ARTHRITIS, RHEUMATOID; BLOOD; CLINICAL TRIAL; EVALUATION STUDY; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MEDICAL SOCIETY; MIDDLE AGED; MULTICENTER STUDY; PRACTICE GUIDELINE; RHEUMATOLOGY;

ADULT; AGED; ALBERTA; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; PRACTICE GUIDELINES AS TOPIC; RHEUMATOID FACTOR; RHEUMATOLOGY; SOCIETIES, MEDICAL;

EID: 84940438133     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-015-2985-z     Document Type: Article

References (13)

1. Canadian Institute for Health Information. Health spending in Canada in 2013. [Internet. Accessed December 22, 2014.] Available from: www.cihi.ca/CIHI-ext-portal/internet/en/document/spending+and+health+workforce/spending/release_29oct13_infogra1pg
2. Dartmouth Medical School Center for the Evaluative Clinical Sciences. The care of patients with severe chronic illness: an online report on the Medicare Program by the Dartmouth Atlas Project. [Internet. Accessed December 22, 2014.] Available from: www.dartmouthatlas.org/downloads/atlases/2006_Chronic_ Care_Atlas.pdf
3. Kale MS, Bishop TF, Federman AD, Keyhani S (2011) “Top 5” lists top $5 billion. Arch Intern Med 171:1858–9
4. Welch HG, Schwartz L, Woloshin S (2011) Overdiagnosed: making people sick in the pursuit of health. Beacon, Boston
5. Chow SL, Thorne C, Bell MJ, Ferrari R, Bagheri Z, Boyd T et al (2015) Choosing wisely Canada. Canadian rheumatology association: five things physicians and patients should question. J Rheumatol. doi:10.3899/jrheum.141140, Published online January 27
6. Suarez-Almazor ME, Gonzalez-Lopez L, Gamez-Nava JI, Belseck E, Kendall CJ, Davis P (1998) Utilization and predictive value of laboratory tests in patients referred to rheumatologists by primary care physicians. J Rheumatol 25:1980–5
7. Kunihiro Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Siago K et al (2007) Meta-analysis: diagnostic accuracy of anti–cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 146:797–808
8. Petri M, Obai AM, Alarcón GS, Gordon C, Merril JT, Fortin PR et al (2012) Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64:2677–86
9. Daniel Aletaha D, Neogi T, Silman AJ, Funovits J, Fleson DT, Bingham CO et al (2010) Rheumatoid arthritis classification criteria. Arthritis Rheum 62:2569–81
10. Yazdany J, Schmajuk G, Robbins M, Daikh D, Beall A et al (2013) Choosing wisely: the american college of Rheumatology’s Top 5 list of things physicians and patients should question. Arthritis Care Res 65:329–39
11. Myckatyn SO, Russell AS (2003) Outcome of positive antinuclear antibodies in individuals without connective tissue disease. J Rheumatol 30:736–9
12. Humphreys JA, Verstappen SM, Hyrich KL, Chipping JR, Marshall T, Symmons D (2013) The incidence of rheumatoid arthritis in the UK: comparisons using the 2010 ACR/EULAR classification criteria and the 1987 ACR classification criteria. Results from the Norfolk arthritis register. Ann Rheum Dis 72:1315–20
13. Scolnik M, Marin J, Valeiras SM, Marchese MF, Talani AS et al (2014) Incidence and prevalence of lupus in Buenos Aires, Argentina: a 11-year health management organisation-based study. Lupus Sci Med 1(1):e000021. doi:10.1136/lupus-2014-000021